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Manganese (Mn), is a trace metal required for normal physiological processes in humans.
Mn levels are tightly regulated, as high levels of Mn result in accumulation in the brain and
cause a neurological disease known as manganism. Manganism shares many similarities
with Parkinson’s disease (PD), both at the physiological level and the cellular level. Exposure
to high Mn-containing environments increases the risk of developing manganism. Mn is
absorbed primarily through the intestine and then released in the blood. Excessive Mn is
secreted in the bile and excreted in feces. Mn enters and exits cells through a number
of non-speciﬁc importers localized on the cell membrane. Mutations in one of the Mn
exporters, SLC30A10 (solute carrier family 30, member 10), result in Mn induced toxicity
with liver impairments and neurological dysfunction. Four PD genes have been identiﬁed
in connection to regulation of Mn toxicity, shedding new light on potential links between
manganism and PD.
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INTRODUCTION
Manganese (Mn) is present in biological organisms in trace
amounts and is necessary for optimal functioning of mul-
tiple enzymes, such as hydrolases, lyases, glutamine syn-
thetase, and superoxide dismutase (SOD; Friberg et al., 1979;
Wedler and Denman, 1984). Mn is also an essential cofactor for
arginase (Roholt and Greenberg, 1956), an enzyme required for
elimination of ammonia, as well as SOD, the principle mitochon-
drial antioxidant enzyme (McCord, 1976). In addition to these
essential functions, Mn modulates the immune system, cell adhe-
sion, as well as protein and carbohydrate metabolism (Grinnell,
1984; Smialowicz et al., 1985). Mn is required for proper bone
and brain development (Frost et al., 1959; Sandstead, 1986), and
Mn deﬁciency, while rare due to abundant Mn in the diet, can
result in birth defects and seizures (Aschner, 2000, 2002). Mn
levels are tightly regulated; however, excessive exposure to this
metal may result in elevated brain accumulation and subsequent
neurodegeneration, referred to as manganism.
Toxic exposures to Mn are most commonly seen in miners
(Rodier, 1955), welders (Racette et al., 2001), and individuals
working in and living around ferroalloy plants (Lucchini et al.,
2007). As observed by T1-weighted magnetic resonance imag-
ing (MRI), excessive levels of Mn accumulate preferentially in
the basal ganglia (Inoue et al., 1991; Kulisevsky et al., 1992; Pujol
et al., 1993; Butterworth et al., 1995; Weissenborn et al., 1995;
Lucchini et al., 2000). The symptoms of idiopathic Parkinson’s
disease (PD) overlap considerably, but not completely, with
manganism. In PD, the earliest symptoms include loss of smell
and sleep disorders, followed by difﬁculty with balance, gait
disturbance, and unilateral resting tremor (Parkinson, 2002).
Presentation varies considerably among patients. The disease
typically progresses to include bradykinesia, rigidity, postural
instability, masked facial expression, and difﬁculty with speech
and swallowing. PD patients may develop visual symptoms,
including a decline in visual perception, disturbances of visu-
ospatial orientation, facial recognition problems, and chronic
visual hallucinations (Armstrong, 2011). A substantial portion of
PD patients also experience depression and/or dementia. Neu-
ropathologically, PD is characterized by the loss of dopaminergic
(DAergic) neurons in the substantia nigra (SN) pars compacta,
and the presence of Lewy bodies, neuronal protein aggregates that
are composed of alpha-synuclein and other proteins (Jellinger,
2012).
NEUROTOXICITY INDUCED BY Mn EXPOSURE
HISTORY AND SYMPTOMS OF MANGANISM
Mn toxicity was ﬁrst described by Couper (1837) reporting his
observations of ﬁve manganese ore crushers with muscular weak-
ness, paraplegia, tremor, whispering speech, and a tendency to
lean forward while walking. In two of the workers, symptoms pro-
gressed even after removal from the Mnore crushing operations.
The remaining three workers were removed from Mn exposure at
the ﬁrst signs of muscle weakness in the lower extremities. In these
three workers, the symptoms abated following removal from Mn
exposure. Manganism was also described by Rodier (1955) in a
group of Moroccan miners, by Mena et al. (1967) in a group of
Chilean miners, and by Huang et al. (1989) in six Taiwanese fer-
romanganese plant workers. Of ∼4000 miners working in three
mines in Morocco, Rodier saw 150 cases of manganism, all in
workers who spent considerable time underground, presumably
with limited ventilation and a high degree of inhalation expo-
sure. In these workers, onset of symptoms occurred after months
to years of work. In contrast, Racette (2013) noted that contem-
porary exposures are much lower, and onset of symptoms tends
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to occur after years or decades of exposure. Mena described Mn
turnover in patients compared to healthy miners using injected
54Mn radioisotope and found signiﬁcantly faster turnover rates in
the healthy miners as compared to miners diagnosed with man-
ganism. Huang described six patients who worked in a factory
with inadequate ventilation. Follow up studies on these patients
indicate that after removal from Mn exposure, their symptoms
continued to worsen for approximately ten years, after which
their condition remained constant with severe extrapyramidal
dysfunction (Huang et al., 1993, 1998, 2007). Early features of
manganism include weakness, anorexia, behavioral, and psychi-
atric disturbances, difﬁculty sleeping, impotence, and attention
disorders. This early stage is characterized by emotional labil-
ity that has been termed “manganese madness.” Patients have
described an awareness that their behavior is unusual or abnor-
mal, but an inability to control their outward affect. There is some
evidence that if Mn exposure is discontinued at an early stage,
these symptoms may revert. However, with acute exposure, pro-
gression often occurs even after Mn exposure has ceased. MRI
shows clearing of Mn from the globus pallidus (GP) in three to
six months (Roth, 2009). In some patients with severe exposure,
neurodegenerative signs progress even after removal from expo-
sure. Later symptoms include extrapyramidal deﬁcits including
bradykinesia, rigidity, difﬁculty with gait, speciﬁcally a dystonic
movement of the foot known as “cock walk,” and a tendency to
fall backward. Masked facial expressions and micrographia are
also present in manganism, as in PD (Couper, 1837; Rodier, 1955;
Mena et al., 1967). Tremor in manganism tends to be slight or
absent as compared to PD. Manganism patients do not typically
respond therapeutically to L-DOPA (Shinotoh et al., 1997; Koller
et al., 2004).
MANGANISM AND PARKINSON’S DISEASE: SIMILARITY AND
DIFFERENCES
There is evidence that genes involved in susceptibility to PD are
also involved in Mn uptake and homeostasis (discussed in more
detail below), leading to the hypothesis that there are common
mechanisms of neurodegeneration to manganism and PD. In each
cohort, only a subset of exposed individuals developed signs of
manganism. It is unknown why some individuals are apparently
able to maintain Mn homeostasis in the presence of high expo-
sures, while others accumulate toxic levels of the metal leading
to neurodegeneration, or why some individuals improve follow-
ing cessation of exposure, while others progress. The distinction
between manganism and PD is typically made based on exposure
history, however, in areas with high levels of naturally or industri-
ally occurring Mn, PD prevalence is higher than in surrounding
regions or national registries (Lucchini et al., 2007), indicating that
the distinction between PD and manganism may not be entirely
clear, especially for chronic, long-term exposures. Understanding
the molecular genetics of Mn transport and toxicity may lead to a
new understanding of the mechanisms underlying PD.
FACTORS REGULATING Mn TRANSPORT AND TOXICITY
ENVIRONMENTAL FACTORS
As the 5th most abundant metal and the 12th most abundant
element on the earth, Mn is present in air, soil, and water. Mn
is taken up primarily through the intestine and then circulated
in the blood (Davis et al., 1993; Finley et al., 1994). Excessive Mn
is secreted via the bile, returning to the intestine and excreted in
feces (Davis et al., 1993;Malecki et al., 1996).Mnmay also enter the
human body by inhalation of fumes containing the metal (Jorge
da Silva et al., 2008). It is also secreted through urine and sweat,
but in smaller amounts (vs. bile; Cohn and Emmett, 1978; Davis
et al., 1993).
Given the abundance of Mn in the environment, humans are
exposed to different levels of Mn. Rice, nuts, whole grains, and
legumes, as well as green vegetables, tea, and certain fruits contain
high Mn levels (ATSDR, 2012). Food-borne Mn levels generally
supply the basic dietary requirement for humans without causing
disease. However, excessive exposure to environmental Mn results
in toxicity. Workers in mining, welding, and smelting industries
may be potentially exposed to high Mn levels (Criswell et al., 2012;
Racette et al., 2012), as well as individuals residing in the vicinity of
Mn associated industries. Exposures to high Mn levels have been
associatedwith greater risk for PD (Racette et al., 2012; Smith et al.,
2012). Additional exposures to Mn have been documented from
gasoline, steel, ﬁreworks, batteries, leather, glass, ceramics, cosmet-
ics, and textiles, as well as certain pesticides and fungicides (such
as Maneb and Mancozeb; ATSDR, 2012). In addition to exposure
in high Mn containing environments, patients with dysfunctional
biliary system (e.g., those requiring parenteral nutrition) are also
more susceptible to Mn induced toxicity, as optimal liver function
is required for Mn secretion. In addition, infants and children that
receive Mn-containing supplements may be at risk to Mn toxi-
city, as younger individuals tend to absorb and maintain higher
Mn levels compared to adults reﬂecting a greater requirement for
Mn in cellular activities (Keen et al., 1986; Zlotkin et al., 1995).
Iron (Fe)-deﬁcient individuals are also at a greater risk for Mn
poisoning, as the two metals compete for shared transporters (see
below). In recent years, Methcathinone abuse has been linked to
manganism, due to the presence of Mn as an impurity (derived
from potassium permanganate; Sikk et al., 2013).
GENETIC FACTORS
Transporters importing extracellular Mn (Table 1)
Mn enters cells by various transporters (importers) located at the
plasmamembrane. These transporters are tightly regulated,main-
taining optimal Mn levels in cells. The divalent metal transporter
1 (DMT1) is the primary divalent Mn (Mn2+) transporter. It
is localized at the plasma membrane (Burdo et al., 2001a) and
functions to import Mn2+ from the extracellular matrix into
cells (Bell et al., 1989; Aschner and Gannon, 1994; Erikson and
Aschner, 2002; Garrick et al., 2003; Au et al., 2009). DMT1 is highly
expressed in basal ganglia, such as SN, GP, hypothalamic nucleus,
and striatum (Williams et al., 2000; Burdo et al., 2001b; Huang
et al., 2004), areas that are known to accumulate high Mn levels
(Suzuki et al., 1975; Newland et al., 1989; Rose et al., 1999; Ikeda
et al., 2000; Jorge da Silva et al., 2008). In addition to DMT1, other
transmembrane proteins also import Mn2+, including the citrate
transporter (Crossgrove et al., 2003), zinc transporters ZIP8 (He
et al., 2006; Himeno et al., 2009; Fujishiro et al., 2011), calcium
channels (Mason, 1993; Lucaciu et al., 1997; Finley, 1998), the
choline transporter (Lockman et al., 2001), dopamine transporter
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Table 1 | Different types of Mn transporters in a cell.
Types of Mn
transporters
Name Localization Roles in Mn transportation
Importers DMT1, ZIP8, citrate transporter,
calcium channels, choline transporter,
DAT, ATP13A2, TfR
Plasma membrane Import extracellular Mn into cytoplasm
Exporters Fpn, SLC30A10 Plasma membrane Export cytosolic Mn to extracellular matrix
Intracellular
transporters
Ca2+uniporter Mitochondrial membrane Import cytosolic Mn into the mitochondria
lumen
Na+-independent mechanisms Mitochondrial membrane Export mitochondrial Mn to cytosol
SPCA1 Golgi membrane Import cytosolic Mninto the Golgi lumen
(DAT; Ingersoll et al., 1999), and a cation-transporting ATPase
13A2 (ATP13A2 or Park9; Gitler et al., 2009; Tan et al., 2011).
Trivalent Mn (Mn3+) enters cells primarily via the transferrin
receptor (TfR) mechanism (Morris et al., 1992). Notably, none
of these proteins is a speciﬁc Mn transporter, and they transport
additional metals, such as iron, calcium, zinc, etc. Currently, few
human diseases are known to be associated with mutations in
these importers, with the exception of Park9 and DMT1. Park9
represents a well-known risk factor for PD. High levels of Fe
were found in brain due to altered DMT1 expression (Urrutia
et al., 2013). Mutations in DMT1 that impair Fe transport pro-
tect rodents against parkinsonism-inducing neurotoxins, such as
MPTP and 6-hydroxydopamine (Salazar et al., 2008), consistent
with a role for DMT1 in Fe-mediated neurodegeneration in PD.
He et al. (2011) reported that the CC haplotype in the DMT1 gene
is a possible risk factor for PD in the Han Chinese population.
Whether mutations in DMT1 alter Mn levels in the brains of these
individuals has yet to be determined.
Transporters exporting intracellular Mn (Table 1)
Cells export excessive Mn from the cytoplasm to the extracellu-
lar matrix, as high Mn levels result in cellular toxicity. Recently,
ferroportin (Fpn) was recognized as putative Mn exporter. It
transports extracellularly both Fe2+ and Mn2+ (Yin et al., 2010;
Madejczyk and Ballatori, 2012). To date, no human diseases
have been ascribed to mutations or dysfunction of this protein,
indicating that Fpn is unlikely to be the primary Mn exporter.
Recently, a gene named SLC30A10 (solute carrier family 30
member 10) was identiﬁed in patients with hepatic cirrhosis,
dystonia, polycythemia, and hypermanganesemia, concomitant
with high Mn brain levels (Quadri et al., 2012; Stamelou et al.,
2012; Tuschl et al., 2012). SLC30A10 is localized at the cell
membrane, and mutations in this gene either result in early
truncation of this protein or amino acid substitution (Quadri
et al., 2012; Stamelou et al., 2012; Tuschl et al., 2012). Inter-
estingly, none of the patients were exposed to excessive Mn,
yet they displayed symptoms consistent with PD (Quadri et al.,
2012; Stamelou et al., 2012; Tuschl et al., 2012). SLC30A10 is
the only protein known to cause Mn toxicity when mutated,
indicating it may be a primary and a key regulator of Mn
export. Our recent data have shown that the wildtype (WT)
SLC30A10protein when expressed in in Caenorhabditis elegans
(C. elegans), protects against Mn2+ induced lethality and DAergic
neurodegeneration, as well as locomotion deﬁcits (basal slowing
response, which is regulated by DAergic neurons; unpublished
data). It remains unclear whether SCL30A10 is a speciﬁc Mn
exporter or if it also transports additional metals. Notably, it was
originally posited to be a speciﬁc zinc transporter (Seve et al.,
2004; Bosomworth et al., 2012). Further research is needed to
better understand its function and a compound screen could
be proﬁtably directed at identifying speciﬁc modulators of this
transporter, potentially leading to novel therapies in patients with
manganism.
Intracellular Mn transporters (Table 1)
Once inside the cell, Mn is transported into various organelles to
fulﬁll its function, thus limiting its potential toxicity from accu-
mulating at high levels in the cytosol. The mitochondria contain
the highest Mn levels (Gavin et al., 1999). Mitochondrial SOD
requires Mn as a cofactor for optimal function (Borgstahl et al.,
1992). The calcium (Ca2+) uniporter imports cytosolic Mn2+
into the mitochondria lumen (Drahota et al., 1969; Gunter and
Puskin, 1972; Gunter et al., 1975), and excessive Mn2+ is exported
out of mitochondria through sodium (Na+)-independent mecha-
nisms (Gavin et al., 1990). The Golgi apparatus can store excessive
Mn2+ and this is mediated by Ca2+/Mn2+ ATPase isoform 1
(SPCA1). SPCA1 is localized at the Golgi membrane and imports
Mn2+ from the cytosol to the Golgi lumen (Murin et al., 2006).
Mn in the Golgi is secreted extracellularly through a secre-
tory pathway. Although the nucleus also contains high levels of
Mn, the transporters localized to the nuclear membrane remain
unknown and future studies are needed to identify these Mn
transporters.
PD-associated proteins involved in Mn-induced toxicity (Table 2 )
As described above, manganism shares many similar symp-
toms with PD. ATP13A2 and DAT both are able to transport
Mn. Notably mutations in ATP13A2 cause a parkinsonian-like
syndrome, Kufor-Rakeb syndrome (KRS). KRS is an autoso-
mal recessive disorder characterized by subacute, juvenile-onset,
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Table 2 | PD-associated proteins involved in Mn-induced toxicity.
PD-associated
proteins
Cellular activity Roles in Mn toxicity
ATP13A2 Inorganic cation transporter Importing extracellular Mn into cytoplasm
DAT DA transporter Importing extracellular Mn into cytoplasm
Parkin E3 ubiquitin ligase Enhancing Mn accumulation when mutated
DJ-1 Antioxidant peptidase Enhancing Mn accumulation when mutated
α-synuclein Presynaptic protein in synaptic vesicle trafﬁcking
and recycling
Reducing Mn accumulation in parkin and DJ-1 mutants
UCH-L1 Ubiquitin ligase Unknown
NURR1 Transcription factor Unknown
PINK1 Serine/threonine kinase Unknown
LRRK2 Protein kinase Unknown
and is levodopa-responsive. It is unknown whether mutations
in ATP13A2 change its afﬁnity for different cations, speciﬁcally
Mn, resulting in increased Mn accumulation in the brain. DAT
removes synaptic dopamine into the presynaptic membrane for
recycling. In PD patients, DAT activity is signiﬁcantly decreased
(Sossi et al., 2007). In C. elegans, dat knockout mutants are
resistant to DAergic neurodegeneration induced by Mn expo-
sure, but show a lower survival rate (Benedetto et al., 2010).
Mutations in α-synuclein, parkin, and DJ-1, all of which are asso-
ciated with early onset PD, have also been shown to alter Mn
transport (Bornhorst et al., 2014). α-synuclein encodes a presy-
naptic protein involved in synaptic vesicle trafﬁcking and recycling
(Gitler et al., 2008; Ben Gedalya et al., 2009). Point mutations
(A30P and A53T) or duplication of α-synuclein result in loss
of DAergic neurons concomitant with oxidative stress, protein
aggregation, and Lewy bodies formation (Narhi et al., 1999; Hsu
et al., 2000; Masliah et al., 2000; Kuwahara et al., 2006), the hall-
marks of PD. Parkin encodes an E3 ubiquitin ligase (Shimura
et al., 2000) responsible for degradation of abnormal proteins.
Mutations in parkin result in DAergic neurodegeneration with
increased oxidative stress, yet in the absence of Lewy bodies (Yang
et al., 2006). It is known that overexpression of parkin is able to
decrease α-synuclein protein aggregation (Petrucelli et al., 2002;
Yang et al., 2003). DJ-1 encodes a protein of the peptidase C56
family. It functions as a peroxidase (Andres-Mateos et al., 2007),
a chaperone (Shendelman et al., 2004), a metal binding protein
(Björkblom et al., 2013), and a regulatory subunit of an RNAbind-
ing complex (Hod et al., 1999), thus protecting cells fromoxidative
stress (Mitsumoto and Nakagawa, 2001; Mitsumoto et al., 2001),
α-synuclein aggregation (Zhou et al., 2009), and metal induced
cell death (Björkblom et al., 2013). It also regulates androgen
receptor-dependent transcription (Takahashi et al., 2001). Muta-
tions in DJ-1 result in increased oxidative stress and DAergic
neurodegeneration. Recently, Chakraborty and colleagues found
that pdr-1 (worm homolog of parkin) and djr-1.1 (worm homolog
of DJ-1) mutants show enhanced Mn accumulation and increased
oxidative stress in C. elegans and these effects may be reduced
by expression of WT human α-synuclein (Bornhorst et al., 2014).
Interestingly,WT α-synuclein also protected against DAergic neu-
rodegeneration induced by Mn exposure in pdr-1 (the homolog
of mammalian parkin/PARK2) mutant worms (Bornhorst et al.,
2014).
In addition to the above proteins, there are other PD-
associated proteins whose effect on Mn-induced toxicity remains
unknown. These PD genes include ubiquitin carboxy-terminal
hydrolase L1 (UCH-L1), NUR-Related factor 1 (NURR1), PTEN-
INduced Kinase 1 (PINK1) and Leucine-Rich Repeat Kinase 2
(LRRK2). UCH-L1 (or PARK5) is an enzyme expressed in neu-
rons throughout the brain that hydrolyzes C-terminal ubiquitinyl
esters to recycle ubiquitin after degradation of misfolded pro-
teins (Wilkinson, 2000; Meray and Lansbury, 2007). Similar to
parkin, it also functions as an ubiquitin ligase to prevent pro-
tein aggregation (Liu et al., 2002; Gong et al., 2006; Lansbury,
2006). NURR1 is a transcription factor predominantly expressed
in central DAergic neurons (Bäckman et al., 1999; Jankovic et al.,
2005). It is critical for development and maintenance of the DAer-
gic system as it regulates the expression of tyrosine hydroxylase
(TH; Sakurada et al., 1999), DAT (Sacchetti et al., 2001), vesicu-
lar monoamine transporter 2 (VMAT2), and aromatic L-amino
acid decarboxylase (AADC; Hermanson et al., 2003). PINK1
(or PARK6) is a mitochondrial targeted serine/threonine kinase,
with substrates in the cytosol (Zhou et al., 2008). Recent stud-
ies indicate that PINK1, together with parkin, is involved in a
mitochondrial quality control system to regulate mitochondrial
dynamics and function, andprotects against cellular stress (Valente
et al., 2004; Clark et al., 2006). LRRK2 or PARK8 is a protein
kinase expressed preferentially in DAergic neurons (Han et al.,
2008). It interacts with parkin in the cytosol and overexpres-
sion of either WT LRRK2 or gain-of-function mutants results in
DAergic neurodegeneration (Smith et al., 2005). Together, these
proteins either interact with parkin or have similar function to
parkin. Given that parkin is involved in regulation of Mn tox-
icity, these PD-related proteins may play a role in Mn-induced
toxicity. Future studies could be proﬁtably directed at the stud-
ies on how mutations in these genes enhance basal ganglia Mn
accumulation.
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CONCLUSION
Mn is required for multiple physiological processes. It is a cofac-
tor for various enzymes and plays important roles in mediating
oxidative stress responses, regulation of immune responses, car-
bohydrate metabolism, energy production, cell adhesion and
protein modiﬁcation (Benedetto et al., 2009). Although Mn deﬁ-
ciency results in birth defects and poor bone development, given
its abundant and ubiquitous presence in the environment, Mn
overexposure represents a more critical contemporary concern.
Excessive accumulation of Mn in the brain may cause DAergic
neurodegeneration and manganism, the latter sharing a clinical
picture analogous to PD. At the cellular level, excessive Mn levels
have been associated with increased oxidative stress, impairedATP
production, protein aggregation and mitochondrial dysfunction.
α-synuclein aggregation or Lewy bodies are absent in the brains
of manganism patients. Given the similarities between mangan-
ism and PD, Mn is considered an important environmental factor
in causing sporadic PD, especially given recent discoveries that
certain PD genes (ATP13A2, parkin, DJ-1, and α-synuclein) are
involved in Mn transport and/or toxicity.
Genetic factors associated with Mn toxicity remain to be
explored. Several Mn importers have been identiﬁed; however,
none have mutations associated with Mn related diseases. Com-
pared to the plethora of Mn importers, knowledge about Mn
exporters is limited. Fpn and SCL30A10 are the only two exporters
identiﬁed to date. Among all known Mn transporters, SLC30A10
appears to be a key regulator of Mn homeostasis, given that
mutations in this genecan result in manganism in the absence of
overexposure to this metal. SLC30A10 localizes at the cell mem-
brane, exports Mn from cells and affords protection in various
experimental models.
Several PD associated genes, namely, either transport Mn
(ATP13A2; Gitler et al., 2009; Tan et al., 2011) or mediate Mn-
induced toxicity (parkin, DJ-1, and α-synuclein; Bornhorst et al.,
2014). These results tightly correlate PD with Mn toxicity, sup-
porting the idea of Mn as an environmental factor of PD. It will
be of particular interest to study brain Mn levels in PD patients
carrying mutations in these genes. Given the similarity between
manganism and PD, it is possible that other well known PD genes
(UCH-L1, NURR1, PINK1, and LRRK2) also play a role in regu-
lating Mn homeostasis. Future studies should be focused on the
relationship between PD-associated proteins and their potential
to alter Mn transport and/or toxicity.
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